Learn more →
Back to Expert Scholars
dermatologic-oncology / dermatologic-oncologyCutaneous T-Cell Lymphoma

Youn Kim

金允

MD

🏢Stanford University School of Medicine(斯坦福大学医学院)🌐USA

Professor of Dermatology; Director, Multidisciplinary Cutaneous Lymphoma Program皮肤科教授;多学科皮肤淋巴瘤项目主任

65
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Youn Kim is the world's leading expert in cutaneous T-cell lymphoma (CTCL), directing Stanford's comprehensive CTCL program. She developed novel staging systems and prognostic tools for mycosis fungoides and Sézary syndrome, led trials that established mogamulizumab and brentuximab vedotin for advanced CTCL, and set global disease management standards.

Share:

🧪Research Fields 研究领域

Dermatologic Oncology皮肤肿瘤学
Cutaneous T-Cell Lymphoma皮肤T细胞淋巴瘤
Mycosis Fungoides蕈样肉芽肿
Sézary SyndromeSézary综合征

🎓Key Contributions 主要贡献

CTCL Staging and Prognosis

Led the development and international validation of the revised ISCL/EORTC staging system for CTCL, providing a globally adopted framework for disease classification and prognosis.

Novel CTCL Therapeutics

Conducted pivotal trials of mogamulizumab and brentuximab vedotin in advanced CTCL, establishing two new FDA-approved agents with demonstrated superiority over standard therapies.

Comprehensive CTCL Disease Management

Developed evidence-based multi-modality treatment algorithms for CTCL integrating skin-directed and systemic therapies, serving as the foundation for NCCN guidelines.

Representative Works 代表性著作

[1]

Mogamulizumab versus Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma (MAVORIC)

Lancet Oncology (2018)

Demonstrated superior progression-free survival with mogamulizumab over vorinostat in relapsed CTCL, supporting FDA approval and establishing a new treatment standard.

[2]

TNM Classification System for Primary Cutaneous Lymphomas

Blood (2007)

Co-authored internationally adopted revised ISCL/EORTC staging system for CTCL and primary cutaneous lymphomas, replacing older, inconsistent classification schemes.

[3]

Brentuximab Vedotin in CD30+ Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma (ALCANZA)

Lancet (2017)

Established brentuximab vedotin superiority over standard therapy in CD30+ CTCL, resulting in FDA approval and international adoption.

🏆Awards & Recognition 奖项与荣誉

🏆Society for Investigative Dermatology Distinguished Investigator Award
🏆American Academy of Dermatology Research Award
🏆Cutaneous Lymphoma Foundation Scientific Achievement Award
🏆Stanford Medicine Research Recognition Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 金允 的研究动态

Follow Youn Kim's research updates

留下邮箱,当我们发布与 Youn Kim(Stanford University School of Medicine)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment